Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alkermes plc

Capitalization 4.63B 4.04B 3.65B 3.49B 6.36B 428B 6.61B 43.64B 17.3B 204B 17.36B 16.99B 738B P/E ratio 2026 *
-41.6x
P/E ratio 2027 * 37.3x
Enterprise value 5.67B 4.95B 4.48B 4.28B 7.79B 524B 8.09B 53.46B 21.19B 250B 21.27B 20.82B 905B EV / Sales 2026 *
3.16x
EV / Sales 2027 * 2.9x
Free-Float
90.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.43%
1 week-3.04%
Current month-7.77%
1 month-16.28%
3 months-2.60%
6 months+2.93%
Current year-0.79%
1 week 27.03
Extreme 27.03
28.89
1 month 27.03
Extreme 27.03
33.88
Current year 27.03
Extreme 27.03
35.34
1 year 25.16
Extreme 25.165
36.32
3 years 22.01
Extreme 22.01
36.45
5 years 18.43
Extreme 18.43
36.45
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer - 31/12/2004
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Change 5d. change 1-year change 3-years change Capi.($)
+0.43%-3.04%-18.42%+3.50% 4.63B
-0.72%-4.60%-12.29%-8.00% 42.78B
-0.44%-5.67%+9.59%+22.80% 31.5B
-0.24%-3.29%+14.84%+48.71% 29.99B
+1.10%-5.60%-11.05%-17.93% 27.65B
-0.22%-3.60%+142.48%+304.69% 18.8B
-1.32%-6.10%+47.72%+106.64% 13.87B
+1.48%-4.29%+38.61%+148.23% 12.78B
-0.29%-4.80%+24.93%+0.10% 12.39B
-1.59%-3.85%+115.99%+110.87% 11.76B
Average -0.18%-4.08%+35.24%+71.96% 20.61B
Weighted average by Cap. -0.22%-4.05%+25.89%+57.07%

Financials

2026 *2027 *
Net sales 1.8B 1.57B 1.42B 1.36B 2.47B 166B 2.56B 16.94B 6.71B 79.33B 6.74B 6.59B 287B 1.88B 1.64B 1.48B 1.42B 2.58B 174B 2.68B 17.7B 7.02B 82.92B 7.04B 6.89B 299B
Net income -112M -98.17M -88.69M -84.84M -154M -10.39B -160M -1.06B -420M -4.96B -421M -413M -17.92B 138M 121M 109M 105M 190M 12.8B 198M 1.31B 518M 6.12B 519M 509M 22.1B
Net Debt 1.04B 910M 822M 786M 1.43B 96.29B 1.49B 9.82B 3.89B 46B 3.91B 3.82B 166B 822M 718M 649M 621M 1.13B 76B 1.17B 7.75B 3.07B 36.31B 3.08B 3.02B 131B
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
2,050
Date Price Change Volume
13/03/26 27.76 $ +0.43% 2,896,735
12/03/26 27.64 $ -0.47% 2,597,551
11/03/26 27.77 $ +0.11% 1,638,310
10/03/26 27.74 $ -2.50% 2,471,531
09/03/26 28.45 $ -0.63% 2,027,184
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
27.76USD
Average target price
43.65USD
Spread / Average Target
+57.23%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW